Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.
Clinical guidelines for psoriasis
dermatology
nonbiologic systemic
psoriasis
psoriasis guidelines
skin disease
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
11
11
2019
revised:
10
02
2020
accepted:
14
02
2020
pubmed:
3
3
2020
medline:
22
1
2021
entrez:
3
3
2020
Statut:
ppublish
Résumé
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 2% of the world's population. In this guideline, we focus the discussion on systemic, nonbiologic medications for the treatment of this disease. We provide detailed discussion of efficacy and safety for the most commonly used medications, including methotrexate, cyclosporine, and acitretin, and provide recommendations to assist prescribers in initiating and managing patients on these treatments. Additionally, we discuss newer therapies, including tofacitinib and apremilast, and briefly touch on a number of other medications, including fumaric acid esters (used outside the United States) and therapies that are no longer widely used for the treatment of psoriasis (ie, hydroxyurea, leflunomide, mycophenolate mofetil, thioguanine, and tacrolimus).
Identifiants
pubmed: 32119894
pii: S0190-9622(20)30284-X
doi: 10.1016/j.jaad.2020.02.044
pii:
doi:
Substances chimiques
Piperidines
0
Pyrimidines
0
Thalidomide
4Z8R6ORS6L
Cyclosporine
83HN0GTJ6D
tofacitinib
87LA6FU830
Acitretin
LCH760E9T7
apremilast
UP7QBP99PN
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
1445-1486Informations de copyright
Copyright © 2020 American Academy of Dermatology, Inc. All rights reserved.